Selecting Against Antibiotic-Resistant Pathogens: Optimal Treatments in the Presence of Commensal Bacteria

Bulletin of Mathematical Biology

Volumn 74, Issue 4, 2012, Pages 908-934

  Peña Miller, Rafael ^a,b   Lähnemann, David ^c   Schulenburg, Hinrich ^d   Ackermann, Martin ^e,f   Beardmore, Robert ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e ETH ZURICH   (Switzerland)

^f Eawag ^*  (Switzerland)

Author keywords

Control theory; Evolution of antimicrobial resistance

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; BACTERIUM; BIOLOGICAL MODEL; DRUG EFFECT; GENETIC SELECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METAGENOME; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; METAGENOME; MODELS, BIOLOGICAL; SELECTION, GENETIC;

BACTERIA (MICROORGANISMS);

EID: 84857902537     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-011-9698-5     Document Type: Article

References (40)

1. Alon, U. (2006). An introduction to systems biology. London: Chapman and Hall.
2. Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev., Microbiol., 8(4), 260-271.
3. Beers, M. H., & Fletcher, A. J. (2004). The Merck manual of medical information. Rahway: Merck. (2nd home ed., online version ed.).
4. Bergeron, M., & Ouellette, M. (1998). Preventing antibiotic resistance through rapid genotypic identification of bacteria and of their antibiotic resistance genes in the clinical microbiology laboratory. Clin. Microbiol., 36(8), 2169-2172.
5. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009). Bad bugs, no drugs: no eskape! an update from the infectious diseases society of America. Clin. Infect. Dis., 48(1), 1-12.
6. Chan, C. X., Beiko, R. G., & Ragan, M. A. (2011). Lateral transfer of genes and gene fragments in staphylococcus extends beyond mobile elements. J. Bacteriol., 193(15), 3964-3977.
7. Chastre, J., Wolff, M., Fagon, J.-Y., Chevret, S., Thomas, F., Wermert, D., Clementi, E., Gonzalez, J., Jusserand, D., Asfar, P., Perrin, D., Fieux, F., & Aubas, S. (PneumA Trial Group) (2003). Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA, 290(19), 2588-2598.
8. Dancer, S. J. (2004). How antibiotics can make us sick: the less obvious adverse effects of antimicrobial chemotherapy. Lancet Infect. Dis., 4(10), 611-619.
9. Dethlefsen, L., & Relman, D. A. (2011). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. USA, 108(Suppl), 4554-4561. doi: 10. 1073/pnas. 1000087107.
10. Eagle, H., Fleischman, R., & Levy, M. (1953). "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N. Engl. J. Med., 248(12), 481-488.
11. Ehrlich, P. (1913). Address in pathology on chemotherapeutics: Scientific principles, methods, and results. Lancet, 182, 445-451. doi: 10. 1016/S0140-6736(01)38705-6.
12. el Moussaoui, R., de Borgie, C. A. J. M., van den Broek, P., Hustinx, W. N., Bresser, P., van den Berk, G. E. L., Poley, J.-W., van den Berg, B., Krouwels, F. H., Bonten, M. J. M., Weenink, C., Bossuyt, P. M. M., Speelman, P., Opmeer, B. C., & Prins, J. M. (2006). Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ, 332(7554), 1355.
13. Fleming, A. (1964). Penicillin. In Nobel lectures, physiology or medicine1942-1962. Amsterdam: Elsevier.
14. Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006). The competitive cost of antibiotic resistance in mycobacterium tuberculosis. Science, 312(5782), 1944-1946.
15. Hegreness, M., Shoresh, N., Damian, D., Hartl, D., & Kishony, R. (2008). Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. USA, 105(37), 13977-13981.
16. Kierzenka, J., & Shampine, L. F. (2001). A BVP solver based on residual control and the Matlab PSE. ACM Trans. Math. Softw., 27(3), 299-316.
17. Kirby, W. M., & Craig, W. A. (1981). Theory and applications of pulse dosing: a summary of the symposium. Rev. Infect. Dis., 3(1), 1-3.
18. Kunin, C. M. (1981). Dosage schedules of antimicrobial agents: a historical review. Rev. Infect. Dis., 3(1), 4-11.
19. Lenski, R. E. (1998). Bacterial evolution and the cost of antibiotic resistance. Int. Food Microbiol., 1(4), 265-270.
20. McFarland, L., Elmer, G., & Surawicz, C. (2002). Breaking the cycle: treatment strategies for 163 cases of recurrent clostridium difficile disease. Am. J. Gastroenterol., 97(7), 1769-1775.
21. Michael, M., Hodson, E. M., Craig, J. C., Martin, S., & Moyer, V. A. (2003). Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst. Rev., 1, CD003966.
22. Michel, J.-B., Yeh, P. J., Chait, R., Moellering, R. C. Jr, & Kishony, R. (2008). Drug interactions modulate the potential for evolution of resistance. Proc. Natl. Acad. Sci. USA, 105(39), 14918-14923.
23. Opmeer, B. C., El Moussaoui, R., Bossuyt, P. M. M., Speelman, P., Prins, J. M., & de Borgie, C. A. J. M. (2007). Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia. J. Antimicrob. Chemother., 60(5), 1131-1136.
24. Pépin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., Nguyen, M., Jacob, C.-E., & Lanthier, L. (2005). Emergence of fluoroquinolones as the predominant risk factor for clostridium difficile-associated diarrhea: a cohort study during an epidemic in quebec. Clin. Infect. Dis., 41(9), 1254-1260.
25. Poehlsgaard, J., & Douthwaite, S. (2005). The bacterial ribosome as a target for antibiotics. Nat. Rev., Microbiol., 3(11), 870-881.
26. Rello, J., & Diaz, E. (2001). Optimal use of antibiotics for intubation-associated pneumonia. Intensive Care Med., 27(2), 337-339.
27. Roede, B. M., Bresser, P., El Moussaoui, R., Krouwels, F. H., van den Berg, B. T. J., Hooghiemstra, P. M., de Borgie, C. A. J. M., Speelman, P., Bossuyt, P. M. M., & Prins, J. M. (2007). Three vs 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin. Microbiol. Infect., 13(3), 284-290.
28. Sandegren, L., & Andersson, D. I. (2009). Bacterial gene amplification: implications for the evolution of antibiotic resistance. Nat. Rev., Microbiol., 7(8), 578-588.
29. Segreti, J., House, H. R., & Siegel, R. E. (2005). Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am. J. Med., 118(Suppl 7A), 21S-28S.
30. Smith, H., & Waltman, P. (1995). The theory of the chemostat. Cambridge: Cambridge University Press.
31. Stecher, B., & Hardt, W.-D. (2008). The role of microbiota in infectious disease. Trends Microbiol., 16(3), 107-114.
32. Sullivan, A., Edlund, C., & Nord, C. (2001). Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis., 1(2), 101-114.
33. Surawicz, C. M. (2004). Treatment of recurrent clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol., 1(1), 32-38.
34. Sussmann, H. T. (1972). The "bang-bang" problem for certain control systems in GL(n, r). SIAM J. Control, 10, 470. doi: 10. 1137/0310036.
35. Torella, J. P., Chait, R., & Kishony, R. (2010). Optimal drug synergy in antimicrobial treatments. PLoS Comput. Biol., 6(6), e1000796.
36. Trinh, V., Langelier, M.-F., Archambault, J., & Coulombe, B. (2006). Structural perspective on mutations affecting the function of multisubunit rna polymerases. Microbiol. Mol. Biol. Rev., 70(1), 12-36.
37. Wolkowicz, G. S. K., & Lu, Z. (1992). Global dynamics of a mathematical model of competition in the chemostat: general response functions and differential death rates. SIAM J. Appl. Math., 52(1), 222-233.
38. Xu, M., Zhou, Y. N., Goldstein, B. P., & Jin, D. J. (2005). Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J. Bacteriol., 187(8), 2783-2792.
39. Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R. (2009). Drug interactions and the evolution of antibiotic resistance. Nat. Rev., Microbiol., 7(6), 460-466.
40. Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today, 12(1-2), 34-42.